Akishi Ooi
- Oncology top 2%
- HER2/EGFR in Cancer Research 14
- Peptidase Inhibition and Analysis 9
-
- Sarcoma Diagnosis and Treatment 12
- Lung Cancer Treatments and Mutations 9
- Cancer Research top 5%
- Gastroenterology top 5%
-
- Monoclonal and Polyclonal Antibodies Research 13
-
- Cancer-related gene regulation 12
- PI3K/AKT/mTOR signaling in cancer 9
- Glycosylation and Glycoproteins Research 8
- Co-authors
- Yoh DobashiShioto SuzukiKoji KonoMitsuhiko HanawaTetsu YamaneIsao NakanishiKazuyoshi KunitomoTakuo Takehana
- Journals
- SHILAP Revista de lepidopterología (1 paper)PLoS ONE (1 paper)Cancer (6 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Akishi Ooi
84 papers receiving 3.0k citations
Peers
Comparison fields: 5 of 103
- Oncology 1.6k
- Pulmonary and Respiratory Medicine 1.1k
- Cancer Research 482
- Gastroenterology 140
- Pathology and Forensic Medicine 339
Countries citing papers authored by Akishi Ooi
This map shows the geographic impact of Akishi Ooi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akishi Ooi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akishi Ooi more than expected).
Fields of papers citing papers by Akishi Ooi
This network shows the impact of papers produced by Akishi Ooi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akishi Ooi. The network helps show where Akishi Ooi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Akishi Ooi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2018 | 4 | |
| 3 | 2017 | 9 | |
| 4 | 2016 | 21 | |
| 5 | 2014 | 2 | |
| 6 | 2013 | 9 | |
| 7 | 2013 | 14 | |
| 8 | 2012 | 26 | |
| 9 | 2012 | 18 | |
| 10 | 2010 | 5 | |
| 11 | Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma. | 2009 | 26 |
| 12 | 2007 | 28 | |
| 13 | 2007 | 117 | |
| 14 | 2005 | 250 | |
| 15 | 2005 | 43 | |
| 16 | 2003 | 64 | |
| 17 | 2002 | 173 | |
| 18 | 1991 | 1 | |
| 19 | 1989 | 8 | |
| 20 | 1987 | 11 |
About Akishi Ooi
Akishi Ooi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 86 papers that have together received 3.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Monoclonal and Polyclonal Antibodies Research (13 papers), Cancer-related gene regulation (12 papers), Sarcoma Diagnosis and Treatment (12 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Peptidase Inhibition and Analysis (9 papers), Lung Cancer Treatments and Mutations (9 papers) and Glycosylation and Glycoproteins Research (8 papers). The work is most often cited by research in Oncology (1.6k citations), Pulmonary and Respiratory Medicine (1.1k citations) and Cancer Research (482 citations). Akishi Ooi has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yoh Dobashi, Shioto Suzuki, Koji Kono, Mitsuhiko Hanawa, Tetsu Yamane, Isao Nakanishi, Kazuyoshi Kunitomo, Takuo Takehana, Yasuhisa Takeda and Hideki Fujii. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.